On June 4, 2025, noted analyst Andres Maldonado of HC Wainwright & Co. reaffirmed the "Buy" rating for ImmunityBio, Inc. (IBRX, Financial). The analyst's report continues to indicate strong confidence in the stock. This reiteration of the rating suggests sustained expectations for the company's financial outlook.
The analyst also maintains the price target for ImmunityBio (IBRX, Financial) at USD 8.00, consistent with the previous target. This price target reflects HC Wainwright's sustained positive view on the company's potential market performance. With no changes to the price target or rating, investors are provided with a stable outlook on the stock's performance.
To recap, ImmunityBio (IBRX, Financial) retains a "Buy" recommendation, with a price target of USD 8.00, as per Andres Maldonado of HC Wainwright & Co. This consistency in rating and price target reflects confidence in the company's future prospects.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for ImmunityBio Inc (IBRX, Financial) is $11.40 with a high estimate of $30.00 and a low estimate of $5.00. The average target implies an upside of 320.66% from the current price of $2.71. More detailed estimate data can be found on the ImmunityBio Inc (IBRX) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, ImmunityBio Inc's (IBRX, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
